Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw, +14

New England Journal of Medicine

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier, +7

Journal of Clinical Oncology

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely, +14

The Lancet Oncology

Phase 1/2Neuro-oncologyDose-finding PortionBrain MetastasesMedicine +7

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Alice T. Shaw, Ramaswamy Govindan, +18

Journal of Clinical Oncology

Release and interconversion of P2 receptor agonists by human osteoblast‐like cells

Katherine M. Buckley, Sophie Golding, Janet M. Rice, +2

The FASEB Journal

P2 Receptor AgonistsOsteoporosisCellular PhysiologyP2 ReceptorsOxidative Stress +18

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

James Chih‐Hsin Yang, Sai‐Hong Ignatius Ou, Luigi De Petris, +17

Journal of Thoracic Oncology

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib

Jessica Davies, Michael Martinec, Paul Delmar, +5

Journal of Comparative Effectiveness Research

Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

Peter N. Morcos, Katrijn Bogman, Stanislas Hubeaux, +7

Cancer Chemotherapy and Pharmacology

Electrophysiological EvaluationCardiovascular DiseaseMedicineDiastolic FunctionCardiac Electrophysiology +6

Can coir increase native biodiversity and reduce colonisation of non-indigenous species in eco-engineered rock pools?

Rebecca L. Morris, Sophie Golding, Katherine A. Dafforn, +1

Ecological Engineering

BiodiversityEcological EngineeringEngineeringNon-indigenous SpeciesEco-engineered Rock Pools +5

Efficacy and safety of the ALK inhibitor alectinib in <i>ALK</i>+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, +15

Journal of Clinical Oncology

PathologyPharmacotherapyPre-clinical PharmacologyTranslational PharmacologyMolecular Pharmacology +20